Accula COVID-19 Test Promo
Accula COVID-19 Promo includes:
2 Kits of Accula SARS-CoV-2 Test Cartridges (50 Tests Total)
1 FREE Accula Docking Station
The Accula SARS-CoV-2 Test combines RT-PCR accuracy with a portable platform and elegantly simple workflow to provide fast and convenient rapid PCR-based test results. The test’s patented PCR technology enables rapid exponential amplification while reducing overall thermocycling times, resulting in faster test results.
The Accula SARS-CoV-2 Test performed on the Accula Dock is a molecular in vitro diagnostic test utilizing PCR and lateral flow technologies for the qualitative, visual detection of nucleic acid from SARS-CoV-2 in clinician-collected nasal or nasal mid-turbinate swab specimens or clinician-instructed self-collected (collected on site) nasal swab specimens, collected from individuals suspected of COVID-19 by their healthcare provider.
Features of the Accula SARS-CoV-2 Test include:
• Rapid testing results—RT-PCR SARS-CoV-2 results in 30 minutes
• Streamlined process—CLIA-waived workflow
• Simplified sample collection—nasal swabs and nasal mid-turbinate swabs
• Trusted partner to health care providers—use of system helps prevent transmission during medical procedures and helps protect immuno-compromised patients
• Easy—store at room temperature, no need for refrigeration
• Accurate results—100% positive and negative percent agreement (PPA and NPA) in prospective clinical study
The Accula SARS-CoV-2 Test is a nucleic acid amplification test (NAAT) for detection of SARS-CoV-2 viral RNA in approximately 30 minutes. To perform the test, nasal or nasal mid-turbinate specimens are added to the SARS-CoV-2 buffer to solubilize the sample. An aliquot of the SARS-CoV-2 buffer is then dispensed into an Accula SARS-CoV-2 Test cassette. The test cassette contains two process positive and negative controls, enzymes, OscAR™ reagents, and a detection strip necessary for the full completion of the assay. There are four steps in the process:
1. Lysis of the virus
2. Reverse transcription (RT) of viral RNA to cDNA
3. Nucleic acid amplification by PCR
In just 30 minutes, clinicians can quickly and reliably identify patients who are COVID-19 positive for isolation or deferment of treatment. None of the mutations in the SARS-CoV-2 Variants of Concern - B.1.1.7 (Alpha), B.1.351 (Beta), B.1.617.2 (Delta), and P.1 (Gamma) – are known to impact the Accula SARS-CoV-2 Test performance.